Literature DB >> 16834942

Chemotherapy-induced peripheral neuropathy: underreported and underappreciated.

Maurie Markman1.   

Abstract

Chemotherapy-induced neuropathy is one of the most serious non-life-threatening side effects experienced by patients receiving this group of pharmaceutical agents. Although frequently reversible, some patients may remain with symptoms for the remainder of their lives. Early recognition that "numbness and tingling" in the hands and feet of a patient receiving chemotherapy is due to the antineoplastic drug, with subsequent dose reduction or discontinuation of the offending agent, may prevent the development of serious neurologic dysfunction.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16834942     DOI: 10.1007/s11916-006-0032-0

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  17 in total

Review 1.  Chemotherapy-induced peripheral neuropathy.

Authors:  Stefan Quasthoff; Hans Peter Hartung
Journal:  J Neurol       Date:  2002-01       Impact factor: 4.849

2.  Cisplatin neurotoxicity.

Authors:  J E Mollman
Journal:  N Engl J Med       Date:  1990-01-11       Impact factor: 91.245

3.  Leukemia following chemotherapy for ovarian cancer.

Authors:  J M Kaldor; N E Day; F Pettersson; E A Clarke; D Pedersen; W Mehnert; J Bell; H Høst; P Prior; S Karjalainen
Journal:  N Engl J Med       Date:  1990-01-04       Impact factor: 91.245

Review 4.  Neurotoxicity secondary to antineoplastic drugs.

Authors:  M K Tuxen; S W Hansen
Journal:  Cancer Treat Rev       Date:  1994-04       Impact factor: 12.111

5.  Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy.

Authors:  T J Postma; J J Heimans; M J Muller; G J Ossenkoppele; J B Vermorken; N K Aaronson
Journal:  Ann Oncol       Date:  1998-07       Impact factor: 32.976

6.  Limits to the "benefits" from our oncologic interventions: a case report.

Authors:  M Markman
Journal:  Gynecol Oncol       Date:  2000-08       Impact factor: 5.482

Review 7.  Cardiotoxicity of cancer therapy.

Authors:  Justin D Floyd; Duc T Nguyen; Raymond L Lobins; Qaiser Bashir; Donald C Doll; Michael C Perry
Journal:  J Clin Oncol       Date:  2005-10-20       Impact factor: 44.544

8.  Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity.

Authors:  G Cavaletti; L Marzorati; G Bogliun; N Colombo; M Marzola; M R Pittelli; G Tredici
Journal:  Cancer       Date:  1992-01-01       Impact factor: 6.860

9.  Risk of leukemia after platinum-based chemotherapy for ovarian cancer.

Authors:  L B Travis; E J Holowaty; K Bergfeldt; C F Lynch; B A Kohler; T Wiklund; R E Curtis; P Hall; M Andersson; E Pukkala; J Sturgeon; M Stovall
Journal:  N Engl J Med       Date:  1999-02-04       Impact factor: 91.245

10.  Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group.

Authors:  David H Moore; James Donnelly; William P McGuire; Lois Almadrones; David F Cella; Thomas J Herzog; Steven E Waggoner
Journal:  J Clin Oncol       Date:  2003-11-15       Impact factor: 44.544

View more
  8 in total

1.  Neuropathic Pain in Pediatric Oncology: A Clinical Decision Algorithm.

Authors:  Doralina L Anghelescu; Jessica Michala Tesney
Journal:  Paediatr Drugs       Date:  2019-04       Impact factor: 3.022

2.  Naringin Abrogates Cisplatin-Induced Cognitive Deficits and Cholinergic Dysfunction Through the Down-Regulation of AChE Expression and iNOS Signaling Pathways in Hippocampus of Aged Rats.

Authors:  Yassine Chtourou; Brahim Gargouri; Mohammed Kebieche; Hamadi Fetoui
Journal:  J Mol Neurosci       Date:  2015-04-21       Impact factor: 3.444

3.  The pediatric-modified total neuropathy score: a reliable and valid measure of chemotherapy-induced peripheral neuropathy in children with non-CNS cancers.

Authors:  Laura S Gilchrist; Lynn Tanner
Journal:  Support Care Cancer       Date:  2012-09-20       Impact factor: 3.603

4.  Burden of chemotherapy-induced neuropathy--a cross-sectional study.

Authors:  Anna-Liisa Kautio; Maija Haanpää; Hannu Kautiainen; Eija Kalso; Tiina Saarto
Journal:  Support Care Cancer       Date:  2010-11-16       Impact factor: 3.603

5.  Patient-centered dosing: oncologists' perspectives about treatment-related side effects and individualized dosing for patients with metastatic breast cancer (MBC).

Authors:  Anne L Loeser; Lucy Gao; Aditya Bardia; Mark E Burkard; Kevin M Kalinsky; Jeffrey Peppercorn; Hope S Rugo; Martha Carlson; Janice Cowden; Lesley Glenn; Julia Maues; Sheila McGlown; Andy Ni; Natalia Padron; Maryam Lustberg
Journal:  Breast Cancer Res Treat       Date:  2022-10-06       Impact factor: 4.624

6.  The Experience of Chemotherapy-Induced Peripheral Neuropathy Among Childhood Cancer Survivors.

Authors:  Caroline Mohrmann
Journal:  J Pediatr Oncol Nurs       Date:  2019-05-05       Impact factor: 1.636

7.  Cisplatin liposome and 6-amino nicotinamide combination to overcome drug resistance in ovarian cancer cells.

Authors:  Daniela Catanzaro; Silvia Nicolosi; Veronica Cocetta; Marika Salvalaio; Andrea Pagetta; Eugenio Ragazzi; Monica Montopoli; Gianfranco Pasut
Journal:  Oncotarget       Date:  2018-03-30

8.  Evaluation of neuropathic pain with diverse pathophysiologies in childhood cancers.

Authors:  Hilal Susam Sen; Tugce Aksu Uzunhan
Journal:  North Clin Istanb       Date:  2022-07-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.